CP-673451: Potent Selective PDGFRα/β Inhibitor for Cancer Research

Executive Summary: CP-673451 is an ATP-competitive inhibitor with nanomolar potency against PDGFR-α (IC50 = 10 nM) and PDGFR-β (IC50 = 1 nM) (APExBIO). It displays over 180-fold selectivity for PDGFR-β versus c-Kit in cellular assays. In ATRX-deficient high-grade glioma models, PDGFR inhibition by CP-673451 leads to enhanced cytotoxicity and tumor growth suppression (Pladevall-Morera et al., 2022). Oral administration in xenograft rodents reduces PDGFR-β phosphorylation by >50% for up to 4 hours and inhibits angiogenesis by 70–90%. CP-673451 is insoluble in water but dissolves in DMSO (≥20.9 mg/mL) and ethanol (≥2.39 mg/mL with warming), and is best stored at -20°C for stability (APExBIO).

Biological Rationale

Platelet-derived growth factor receptors (PDGFRα and PDGFRβ) are receptor tyrosine kinases (RTKs) essential for cellular proliferation, angiogenesis, and tumor stroma interactions. Aberrant PDGFR signaling is implicated in various cancers, including glioblastoma, soft tissue sarcoma, and colorectal carcinoma (Pladevall-Morera et al., 2022). Mutations in ATRX, a chromatin remodeler associated with tumor suppression, frequently co-occur with PDGFR amplification and sensitize cells to PDGFR inhibitors. Targeting PDGFRs with selective small-molecule inhibitors like CP-673451 enables precise dissection of tyrosine kinase signaling and angiogenic mechanisms in cancer research (see related article, which focuses on pathway interrogation, while this article details xenograft efficacy and ATRX context).

Mechanism of Action of CP-673451

CP-673451 is a potent, ATP-competitive inhibitor targeting the active kinase domains of PDGFRα and PDGFRβ. It binds to the ATP-binding pocket, preventing autophosphorylation and downstream signal transduction. The compound exhibits IC50 values of 10 nM (PDGFRα) and 1 nM (PDGFRβ) in biochemical assays (APExBIO). Cellular assays in PAE-β cells show inhibition of PDGFR-β phosphorylation with an IC50 of 6.4 nM. CP-673451 demonstrates high selectivity, with >180-fold preference for PDGFR-β over c-Kit in H526 cell assays and negligible activity against VEGFR-1/2, Lck, TIE-2, and EGFR (prior review explained selectivity spectrum; this article quantifies xenograft outcomes).

Evidence & Benchmarks

• CP-673451 inhibits PDGFR-α (IC50 = 10 nM) and PDGFR-β (IC50 = 1 nM) in vitro (APExBIO).
• Shows >180-fold selectivity for PDGFR-β over c-Kit in H526 cell models (APExBIO).
• Oral dosing at 50 mg/kg in rat C6 glioblastoma xenografts reduces PDGFR-β phosphorylation by >50% for 4 hours (APExBIO).
• Inhibits PDGF-BB-induced angiogenesis by 70–90% in mouse sponge assay (APExBIO).
• Suppresses tumor growth and microvessel density in Colo205, LS174T, H460, and U87MG xenograft models (Pladevall-Morera et al., 2022).
• ATRX-deficient high-grade glioma cells exhibit increased sensitivity to PDGFR inhibition by CP-673451 (Pladevall-Morera et al., 2022).
• Combinatorial treatment with temozolomide and PDGFR inhibitors increases cytotoxicity in ATRX-deficient models (Pladevall-Morera et al., 2022).

Applications, Limits & Misconceptions

CP-673451 is used in cancer research for:

• Interrogating PDGFR signaling pathways in vitro and in vivo.
• Evaluating angiogenesis inhibition using mouse sponge and cellular models.
• Studying tumor growth suppression in xenograft models, especially glioblastoma and colorectal cancer.
• Exploring ATRX mutation–dependent drug response and combination therapies (see contrasting article, which offers mechanistic and translational context; the present article emphasizes quantitative benchmarks and storage/solubility parameters).

Common Pitfalls or Misconceptions

• CP-673451 is not effective against kinases such as VEGFR-1, VEGFR-2, Lck, TIE-2, and EGFR at relevant concentrations (APExBIO).
• Ineffective when used in models lacking PDGFR expression or activity.
• Not suitable for aqueous-only formulations due to water insolubility; must use DMSO or ethanol (APExBIO).
• Not validated for clinical use; intended for preclinical research applications only.
• Prolonged solution storage may reduce activity; short-term use and low-temperature storage are recommended.

Workflow Integration & Parameters

Preparation: Dissolve CP-673451 in DMSO (≥20.9 mg/mL) or ethanol (≥2.39 mg/mL with warming and sonication). Stock solutions are stable below -20°C for several months. For in vivo studies, oral administration at 50 mg/kg in rats achieves significant PDGFR-β inhibition within 4 hours. For in vitro assays, use nanomolar concentrations corresponding to cellular IC50 values. Store solid compound at -20°C and minimize freeze-thaw cycles. For angiogenesis or xenograft studies, consult the CP-673451 product page for validated protocols.

Conclusion & Outlook

CP-673451 remains a benchmark selective PDGFRα/β inhibitor for preclinical cancer research, offering robust potency and specificity. Its efficacy in ATRX-deficient high-grade glioma and diverse xenograft models supports its use for dissecting PDGFR-dependent oncogenic mechanisms and testing combinatorial therapies. As new genetic dependencies are discovered in cancer, integrating CP-673451 into research workflows can facilitate deeper mechanistic insights and guide future translational studies. For detailed product and protocol information, refer to APExBIO, the exclusive provider of CP-673451 (SKU: B2173).